

Claims

1. (Currently Amended) A modified follicle stimulating hormone (FSH), containing an amino acid sequence which differs from the wild-type FSH, said modified FSH comprising a modified α -subunit, and a modified β -subunit, wherein the modified β -subunit comprises at least one basic amino acid at a position corresponding to positions 2, 4, 14, 63, 64, 67 and 69, of SEQ ID NO:2, wherein said basic amino acid is an arginine, and wherein the potency of said modified FSH is increased by at least about [[a]] ten fold as compared to wild type FSH.
2. (Original) The modified FSH of claim 1, wherein the potency of said modified FSH is increased by at least about 30 fold as compared to wild type FSH.
3. (Original) The modified FSH of claim 1, wherein the potency of said modified glycoprotein hormone is increased by at least about 50 fold as compared to wild type FSH.
4. (Previously Presented) The modified FSH of claim 1, wherein said modified FSH is selected from the group consisting of human, bovine, equine, porcine, ovine, murine, primate, and fish.
5. (Original) The modified FSH of claim 4, wherein said modified FSH is human.
6. (Previously Presented) The modified FSH of claim 5, wherein said modified α -subunit comprises at least two basic amino acids at positions selected from the group consisting of positions corresponding to 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81 of SEQ ID No:1.
7. (Original) The modified FSH of claim 6, wherein said basic amino acids of the α -subunit are at positions 14 and 66.

8. (Original) The modified FSH of claim 7, wherein said basic amino acids are E14R and N66R.

9. (Original) The modified FSH of claim 6, wherein said basic amino acids of the α -subunit are at positions 14 and 73.

10. (Original) The modified FSH of claim 9, wherein said basic amino acids are E14R and G73R.

11. (Original) The modified FSH of claim 6, wherein said basic amino acids of the α -subunit are at positions 16 and 20.

12. (Currently Amended) The modified FSH of claim 11, wherein said basic amino acids at positions 16 and 20 are ~~P16R and Q20R~~ arginine.

13. (Original) The modified FSH of claim 6, wherein said basic amino acids of the α -subunit are at positions 20 and 21.

14. (Currently Amended) The modified FSH of claim 13, wherein said basic amino acids at positions 20 and 21 are ~~Q20R and P21R~~ arginine.

15. (Original) The modified FSH of claim 6, said α -subunit further comprising a third basic amino acid at a position selected from the group consisting of positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

16. (Original) The modified FSH of claim 15, wherein said basic amino acids of the α -subunit are at positions 16, 20 and 21.

17. (Currently Amended) The modified FSH of claim 16, wherein said basic amino acids at positions 16, 20 and 21 are ~~P16R, Q20R and P21R~~ arginine.

18. (Original) The modified FSH of claim 15, wherein said basic amino acids of the α -subunit are at positions 14, 20 and 73.

19. (Currently Amended) The modified FSH of claim 18, wherein said basic amino acids at positions 14, 20 and 73 are ~~E14R, Q20R and G73R~~ arginine.

20. (Original) The modified FSH of claim 15, wherein said basic amino acids of the α -subunit are at positions 66, 73 and 81.

21. (Currently Amended) The modified FSH of claim 20, wherein said basic amino acids at positions 66, 73 and 81 are ~~N66K, G73K and A81K~~ lysine.

22. (Original) The modified FSH of claim 15, wherein said basic amino acids of the α -subunit are at positions 14, 66 and 73.

23. (Currently Amended) The modified FSH of claim 22, wherein said basic amino acids at positions 14, 66 and 73 are ~~E14R, N66R and G73R~~ arginine.

24. (Original) The modified FSH of claim 15, wherein said basic amino acids of the α -subunit are at positions 14, 21 and 73.

25. (Currently Amended) The modified FSH of claim 24, wherein said basic amino acids at positions 14, 21 and 73 are ~~E14R, P21R and G73R~~ arginine.

26. (Original) The modified FSH of claim 15, said α -subunit further comprising a fourth basic amino acid at a position selected from the group consisting of positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

27. (Original) The modified FSH of claim 26, wherein said basic amino acids of the α -subunit are at positions 13, 14, 16 and 20.

28. (Currently Amended) The modified FSH of claim 27, wherein said basic amino acids at positions 13, 14, 16 and 20 are ~~Q13R, E14R, P16R and Q20R~~ arginine.

29. (Currently Amended) The modified FSH of claim 28, wherein said basic amino acids at positions 13, 14, 16, and 20 are ~~Q13K, E14K, P16K and Q20K~~ lysine.

30. (Original) The modified FSH of claim 26, said α -subunit further comprising a fifth basic amino acid at a position selected from the group consisting of positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

31. (Original) The modified FSH of claim 30, wherein said basic amino acids of the α -subunit are at positions 14, 20, 21, 66 and 73.

32. (Currently Amended) The modified FSH of claim 31, wherein said basic amino acids at positions 14, 20, 21, 66 and 73 are ~~E14R, Q20R, P21R, N66R and G73R~~ arginine.

33. (Original) The modified FSH of claim 30, wherein said basic amino acids of the α -subunit are at positions 14, 16, 20, 66 and 73.

34. (Currently Amended) The modified FSH of claim 33, wherein said basic amino acids at positions 14, 16, 20, 66 and 73 are ~~E14R, P16R, Q20R, N66R and G73R~~ arginine.

35. (Original) The modified FSH of claim 30, said α -subunit further comprising a sixth basic amino acid at a position selected from the group consisting of positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

36. (Original) The modified FSH of claim 35, wherein said basic amino acids of the α -subunit are at positions 13, 14, 16, 20, 66 and 73.

37. (Currently Amended) The modified FSH of claim 36, wherein said basic amino acids at positions 13, 14, 16, 20, 66 and 73 are ~~Q13K, E14K, P16K, Q20K, N66K and G73K~~ lysine.

38. (Original) The modified FSH of claim 35, wherein said basic amino acids of the α -subunit are at positions 14, 16, 20, 21, 66 and 73.

39. (Currently Amended) The modified FSH of claim 38, wherein said basic amino acids at positions 14, 16, 20, 21, 66, and 73 are ~~E14R, P16R, Q20R, P21R, N66R and G73R~~ lysine.

40. (Original) The modified FSH of claim 6, wherein said basic amino acids are selected from the group consisting of lysine and arginine.

41. (Cancelled)

42. (Cancelled)

43. (Currently Amended) The modified FSH of claim 1, wherein said basic amino acid is an arginine at position 4 E4R.

44-46. (Cancelled)

47. (Original) The modified FSH of claim 6, wherein said modified FSH has less than five amino acid substitutions in said α -subunit in positions other than positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

48. (Original) The modified FSH of claim 6, wherein said modified FSH has less than four amino acid substitutions in said α -subunit in positions other than positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

49. (Original) The modified FSH of claim 6, wherein said modified FSH has less than three amino acid substitutions in said α -subunit in positions other than positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

50. (Original) The modified FSH of claim 6, wherein said modified FSH has less than two amino acid substitutions in said α -subunit in positions other than positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

51. (Original) The modified FSH of claim 6, wherein said modified FSH has complete amino acid sequence identity with the corresponding wild-type FSH in said α -subunit in positions other than positions 13, 14, 16, 17, 20, 21, 22, 66, 68, 73, 74 and 81.

52. (Original) The modified FSH of claim 1, wherein the plasma half-life is increased as compared to wild type FSH.

53. (Original) The modified FSH of claim 52, wherein said modified FSH further comprises at least one sequence with a potential glycosylation site selected from the group consisting of a sequence comprising a N-glycosylation site and a sequence comprising an O-glycosylation site.

54. (Original) The modified FSH of claim 53, wherein said at least one sequence with a potential glycosylation recognition site is an N-terminal extension on said a chain.

55. (Previously Presented) The modified FSH of claim 54, wherein said N-terminal extension is selected from the group consisting of ANITV (SEQ ID No: 3) and ANITVNITV (SEQ ID No:4).

56. (Original) The modified FSH of claim 53, wherein said at least one sequence with a potential glycosylation recognition site is a substitution in said P chain.

57. (Currently Amended) The modified FSH of claim 56, wherein said substitution is selected from the group consisting of substitutions at positions 58 and 78 ~~Y58N and V78N~~.

58. (Original) The modified FSH of claim 52, wherein said modified FSH is pegylated.

59. (Original) The modified FSH of claim 52, wherein said modified FSH is altered to increase the number of negatively charged residues within the molecule to increase plasma half-life.

60. (Original) The method of claim 59, wherein said negatively charged residues are selected from the group consisting of glutamate and aspartate.

61. (Currently Amended) The modified FSH of claim 60, wherein said alteration is selected from the group consisting of alpha subunit substitutions of glutamate or aspartate at position 85 A85E and A85D.

62. (Original) The modified FSH of claim 59, wherein said alteration is an insertion of an amino acid sequence containing one or more negatively charged residues into said modified FSH.

63. (Previously Presented) The modified FSH of claim 62, wherein said insertion is selected from the group consisting of GEFT (SEQ ID No: 5) and GEFTT (SEQ ID No: 6).

64. (Original) The modified FSH of claim 63, wherein said insertion is in the alpha subunit.

65. (Original) The modified FSH of claim 64, wherein said insertion is accompanied by a deletion of one or more amino acids.

66. (Previously Presented) The modified FSH of claim 64, wherein said insertion is selected from the group consisting of APD-GEFT-VQDC (SEQ ID No: 7) and APD-GEFTT-QDC (SEQ ID No:8).

67. (Original) A method of assisting reproduction in a subject comprising administering an assisting amount of the modified FSH of claim 1.

68-83. (Cancelled)

84. (Previously Presented) A method of improving the quality of oocytes in an animal comprising: administering an effective amount of a superactive follicle stimulating hormone to said animal, wherein said superactive follicle stimulating hormone contains an α -subunit with a basic amino acid at one or more positions selected from the group consisting of positions 13, 14, 16, and 20 and wherein said superactive follicle stimulating hormone contains a modified β -subunit with a basic amino acid at one or more positions selected from the group consisting of 2, 4, 14, 63, 64, 67 and 69 of SEQ ID NO: 2, wherein said basic amino acid in the β -subunit is arginine.

85. (Original) A method of claim 84, wherein said improvement in the quality of oocytes is characterized by an improvement in fertilization rate of oocytes in the animal as compared to a like animal receiving the same amount of recombinant wild type FSH.

86. (Original) A method of claim 85, wherein the rate of fertilized oocytes increases at least about 10% as a result of administration of said superactive follicle stimulating hormone at the maximally effective dose for oocyte number.

87. (Original) A method of claim 84, wherein said improvement in the quality of oocytes is characterized by an improvement in blastocyst formation rate per fertilized oocyte in the animal compared to a like animal receiving the same amount of recombinant wild type FSH.

88. (Original) A method of claim 87, wherein rate of blastocyst formation increases at least about 10% as a result of administration of said superactive follicle stimulating hormone at the maximally effective dose for oocyte number.

89. (Original) A method of claim 84, wherein said improvement in the quality of oocytes is characterized by an improvement in total number of embryos per fertilized oocyte of the animal compared to a like animal receiving the same amount of recombinant wild type FSH.

90. (Original) A method of claim 89, wherein the total number of embryos per fertilized oocyte increases at least about 10% as a result of administration of said superactive follicle stimulating hormone at the maximally effective dose for oocyte number.

91. (Original) A method of claim 84, wherein the basic amino acid of the alpha-subunit is an arginine, a lysine, a histidine, or a modification thereof.

92. (Original) A method of claim 84, wherein the basic amino acid of the alpha-subunit is positively charged at a neutral pH.

93. (Original) A method of claim 84, wherein the superactive FSH contains an arginine at positions 13, 14, 16, and 20.

94. (Original) A method of claim 84, wherein the superactive follicle stimulating hormone contains a lysine at positions 13, 14, 16, and 20.

95. (Original) A method of claim 84, wherein the alpha-subunit contains a modification to prolong half-life.

96. (Original) A method of claim 95, wherein the modification to prolong half-life is an ANITV extension.

97. (Original) A method of claim 84, wherein the superactive follicle stimulating hormone is a human superactive follicle stimulating hormone.

98. (Original) A method of claim 84, wherein the animal is selected from the group consisting of human, mouse, rat, primate, rabbit, pig, cow, horse, sheep, and dog.

99. (Original) A method of claim 84, wherein the superactive follicle stimulating hormone is administered by injection or ingestion.

100. (Cancelled)

101. (Cancelled)

102. (Original) A method of claim 84, wherein the superactive follicle stimulating hormone contains a alpha-subunit with a basic amino acid at position 4.

103. (Original) The method of claim 102, wherein the basic amino acid is an arginine, a lysine, a histadine, or a modification thereof.

104. (Previously Presented) A method of inducing superovulation in an animal comprising: administering an effective amount of superactive follicle stimulating hormone to said animal, wherein said superactive follicle stimulating hormone contains an alpha-subunit with a basic amino acid at one or more positions selected from the group consisting of positions 13, 14, 16, and 20 and wherein said superactive follicle stimulating hormone contains a modified β -subunit with a basic amino acid at one or more positions selected from the group consisting of 2, 4, 14, 63, 64, 67 and 69 of SEQ ID NO: 2, wherein said basic amino acid in the β -subunit is arginine.

105. (Original) A method of claim 104, wherein superovulation is characterized by an increase in oocyte number as compared to a like animal receiving the same amount of recombinant wild type FSH.

106. (Original) A method of claim 105, wherein the average oocyte number increases at least about 10% as a result of administration of said superactive follicle stimulating hormone at the maximally effective dose for oocyte number.

107. (Previously Presented) The method of claim 104, wherein the basic amino acid of the α -subunit is an arginine, a lysine, a histadine, or a modification thereof.

108. (Previously Presented) A method of claim 104, wherein the basic amino acid of the α -subunit is positively charged at a neutral pH.

109. (Currently Amended) A method of claim 104, wherein the superactive FSH contains an arginine at positions 13, 14, 16, and 20 of the α -subunit.

110. (Previously Presented) the method of claim 104, wherein the superactive follicle stimulating hormone contains a lysine at positions 12, 14, 16 and 20 of the α -subunit.

111. (Original) A method of claim 104, wherein the alpha-subunit contains a modification to prolong half-life.

112. (Previously Presented) A method of claim 111, wherein the modification to prolong half-life is an ANITV (SEQ ID No:3) extension.

113. (Original) A method of claim 104, wherein the superactive follicle stimulating hormone is a human superactive follicle stimulating hormone.

114. (Original) A method of claim 104, wherein the animal is selected from a group consisting of a human, mouse, rat, primate, rabbit, pig, cow, horse, sheep, and dog.

115. (Original) A method of claim 104, wherein the superactive follicle stimulating hormone is administered by injection or ingestion.

116. (Cancelled)

117. (Cancelled)

118. (Original) A method of claim 104, wherein the superactive follicle stimulating hormone contains a alpha-subunit with a basic amino acid at position 4.

119. (Original) The method of claim 118, wherein the basic amino acid is an arginine, a lysine, a histidine, or a modification thereof.

120. (Previously Presented) A method of enhancing in vitro fertilization comprising: administering an effective amount of superactive follicle stimulating hormone to said animal, wherein said superactive follicle stimulating hormone contains an alpha-subunit with a basic amino acid at one or more positions selected from the group consisting of positions 13, 14, 16, and 20 and wherein said superactive follicle stimulating hormone contains a modified β -subunit with a basic amino acid at one or more positions selected from the group consisting of 2, 4, 14, 63, 64, 67 and 69 of SEQ ID NO:2, wherein said basic amino acid in the β -subunit is arginine.

121. (Original) A method of claim 120, wherein the basic amino acid of the alpha-subunit is an arginine, a lysine, a histidine, or a modification thereof.

122. (Original) A method of claim 120, wherein the basic amino acid of the alpha-subunit is positively charged at a neutral pH.

123. (Previously Presented) A method of claim 120, wherein the superactive FSH contains an arginine at positions 13, 14, 16, and 20 of the α -subunit.

124. (Previously Presented) A method of claim 120, wherein the superactive follicle stimulating hormone contains a lysine at positions 13, 14, 16, and 20 of the α -subunit.

125. (Original) A method of claim 120, wherein the alpha-subunit contains a modification to prolong half-life.

126. (Previously Presented) A method of claim 125, wherein the modification to prolong half-life is an ANITV (SEQ ID No:3) extension.

127. (Original) A method of claim 120, wherein the superactive follicle stimulating hormone is a human superactive follicle stimulating hormone.

128. (Original) A method of claim 120, wherein the animal is selected from a group consisting of a human, mouse, rat, primate, rabbit, pig, cow, horse, sheep, and dog.

129. (Original) A method of claim 120, wherein the superactive follicle stimulating hormone is administered by injection or ingestion.

130. (Cancelled)

131. (Cancelled)

132. (Original) A method of claim 120, wherein the superactive follicle stimulating hormone contains a α -subunit with a basic amino acid at position 4.

133. (Original) A method of claim 132, wherein the basic amino acid is an arginine, a lysine, a histidine, or a modification thereof.

134. (Cancelled)

135. (Cancelled)

136. (Original) The modified FSH of claim 1, wherein there is an increase in absorption compared to wild type FSH.

137. (Previously Presented) The modified FSH of claim 1, wherein there is an increase in binding affinity to a FSH receptor compared to wild type FSH.

138. (Currently Amended) A modified follicle stimulating hormone (FSH), containing an amino acid sequence which differs from the wild-type FSH, said modified FSH comprising a modified α -subunit, and a modified β -subunit containing a basic amino acid substitution, wherein the basic amino acid substitution is E4R, and wherein the potency of said modified FSH is increased by at least about ten fold as compared to wild type.